<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80229</article-id><article-id pub-id-type="doi">10.7554/eLife.80229</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Characterization of full-length <italic>CNBP</italic> expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-282081"><name><surname>Alfano</surname><given-names>Massimiliano</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282082"><name><surname>De Antoni</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282083"><name><surname>Centofanti</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282084"><name><surname>Visconti</surname><given-names>Virginia Veronica</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282085"><name><surname>Maestri</surname><given-names>Simone</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1192-0684</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282086"><name><surname>Degli Esposti</surname><given-names>Chiara</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5974-4915</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282087"><name><surname>Massa</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282088"><name><surname>D'Apice</surname><given-names>Maria Rosaria</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208421"><name><surname>Novelli</surname><given-names>Giuseppe</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7781-602X</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-186594"><name><surname>Delledonne</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-282089"><name><surname>Botta</surname><given-names>Annalisa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-279604"><name><surname>Rossato</surname><given-names>Marzia</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6101-1550</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biotechnology</institution>, <institution>University of Verona</institution>, <addr-line><named-content content-type="city">Verona</named-content></addr-line>, <country>Italy</country></aff><aff id="aff2"><institution content-type="dept">Department of Biomedicine and Prevention</institution>, <institution>University of Rome Tor Vergata</institution>, <addr-line><named-content content-type="city">Rome</named-content></addr-line>, <country>Italy</country></aff><aff id="aff3"><institution content-type="dept">Department of Systems Medicine (Neurology)</institution>, <institution>University of Rome Tor Vergata</institution>, <addr-line><named-content content-type="city">Rome</named-content></addr-line>, <country>Italy</country></aff><aff id="aff4"><institution content-type="dept">Laboratory of Medical Genetics</institution>, <institution>University of Rome Tor Vergata</institution>, <addr-line><named-content content-type="city">Rome</named-content></addr-line>, <country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-23994"><name><surname>Choi</surname><given-names>Murim</given-names></name><role>Reviewing editor</role><aff><institution>Seoul National University</institution>, <country>Republic of Korea</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>botta@med.uniroma2.it</email> (AB);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>marzia.rossato@univr.it</email> (MR);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>08</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e80229</elocation-id><history><date date-type="received"><day>12</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>25</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Alfano et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Alfano et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80229-v1.pdf"/><abstract><p>Myotonic dystrophy type 2 (DM2) is caused by CCTG repeat expansions in the <italic>CNBP</italic> gene, comprising 75 to &gt;11,000 units and featuring extensive mosaicism, making it challenging to sequence fully-expanded alleles. To overcome these limitations, we used PCR-free Cas9-mediated nanopore sequencing to characterize <italic>CNBP</italic> repeat expansions at the single-nucleotide level in nine DM2 patients. The length of normal and expanded alleles can be assessed precisely using this strategy, agreeing with traditional methods, and revealing the degree of mosaicism. We also sequenced an entire ~50 kbp expansion, which has not been achieved previously for DM2 or any other repeat-expansion disorders. Our approach precisely counted the repeats and identified the repeat pattern for both short interrupted and uninterrupted alleles. Interestingly, in the expanded alleles, only two DM2 samples featured the expected pure CCTG repeat pattern, while the other seven presented also TCTG blocks at the 3′ end, which have not been reported before in DM2 patients, but confirmed hereby with orthogonal methods. The demonstrated approach simultaneously determines repeat length, structure/motif and the extent of somatic mosaicism, promising to improve the molecular diagnosis of DM2 and achieve more accurate genotype-phenotype correlations for the better stratification of DM2 patients in clinical trials.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005202</institution-id><institution>Muscular Dystrophy Association</institution></institution-wrap></funding-source><award-id>MDA 876149</award-id><principal-award-recipient><name><surname>Delledonne</surname><given-names>Massimo</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Italian DiMio onlus association</institution></institution-wrap></funding-source><award-id>DM0000010</award-id><principal-award-recipient><name><surname>Botta</surname><given-names>Annalisa</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Massimo Delledonne, is a partner of Genartis srl.</p></fn><fn fn-type="conflict" id="conf3"><p>Marzia Rossato, is a partner of Genartis srl, Verona.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study was approved by the institutional review board of Policlinico Tor Vergata (document no. 232/19). All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all nine participants and all samples and clinical information were anonymized immediately after collection using a unique alphanumeric identification code.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The sequencing data generated in this study have been submitted to the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA818354. For revision purposes, reviewers can download data from the following link: https://dataview.ncbi.nlm.nih.gov/object/PRJNA818354?reviewer=1g4lp9ijkgv5s07is6imnot6ch</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Alfano M</collab><collab>et al</collab></person-group><year iso-8601-date="2022">2022</year><source>Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA818354">https://www.ncbi.nlm.nih.gov/bioproject/PRJNA818354</ext-link><comment>NCBI BioProject, PRJNA818354</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-80229-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>